88Q Fundamental Analysis - 4BASEBIO PLC

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to 88Q. 88Q was compared to 81 industry peers in the Biotechnology industry. While 88Q seems to be doing ok healthwise, there are quite some concerns on its profitability. 88Q shows excellent growth, but is valued quite expensive already.

Quickly go to:

1. Profitability

1.1 Basic Checks

88Q had negative earnings in the past year.

88Q had a negative operating cash flow in the past year.

In the past 5 years 88Q always reported negative net income.

In the past 5 years 88Q always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -39.08%, 88Q perfoms like the industry average, outperforming 43.21% of the companies in the same industry.

With a Return On Equity value of -75.90%, 88Q perfoms like the industry average, outperforming 51.85% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-39.08%
ROE	-75.9%
ROIC	N/A

ROA(3y)-45.31%

ROA(5y)-32.39%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

88Q has a Gross Margin (61.55%) which is comparable to the rest of the industry.

In the last couple of years the Gross Margin of 88Q has declined.

88Q does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	61.55%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-5.33%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

88Q does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for 88Q has been increased compared to 1 year ago.

Compared to 5 years ago, 88Q has more shares outstanding

88Q has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of 1.34, we must say that 88Q is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of 1.34, 88Q is in the better half of the industry, outperforming 61.73% of the companies in the same industry.

A Debt/Equity ratio of 0.81 indicates that 88Q is somewhat dependend on debt financing.

The Debt to Equity ratio of 88Q (0.81) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.81
Debt/FCF	N/A
Altman-Z	1.34

ROIC/WACCN/A

WACC8.33%

2.3 Liquidity

88Q has a Current Ratio of 11.36. This indicates that 88Q is financially healthy and has no problem in meeting its short term obligations.

88Q has a better Current ratio (11.36) than 95.06% of its industry peers.

88Q has a Quick Ratio of 11.15. This indicates that 88Q is financially healthy and has no problem in meeting its short term obligations.

Looking at the Quick ratio, with a value of 11.15, 88Q belongs to the top of the industry, outperforming 95.06% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	11.36
Quick Ratio	11.15

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for 88Q have decreased strongly by -26.52% in the last year.

Looking at the last year, 88Q shows a very strong growth in Revenue. The Revenue has grown by 198.49%.

The Revenue has been growing by 35.80% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)-26.52%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-11.8%

Revenue 1Y (TTM)198.49%

Revenue growth 3Y40.28%

Revenue growth 5Y35.8%

Sales Q2Q%257.93%

3.2 Future

88Q is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.34% yearly.

The Revenue is expected to grow by 97.35% on average over the next years. This is a very strong growth

EPS Next Y-34.32%

EPS Next 2Y-7.14%

EPS Next 3Y2.5%

EPS Next 5Y10.34%

Revenue Next Year50%

Revenue Next 2Y141.52%

Revenue Next 3Y132.08%

Revenue Next 5Y97.35%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for 88Q. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 88Q. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-7.14%

EPS Next 3Y2.5%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for 88Q!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

4BASEBIO PLC

FRA:88Q (12/22/2025, 7:00:00 PM)

6.5

-0.5 (-7.14%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)N/A N/A

Earnings (Next)05-25 2026-05-25

Inst Owners13.48%

Inst Owner ChangeN/A

Ins Owners10.92%

Ins Owner ChangeN/A

Market Cap101.01M

Revenue(TTM)1.78M

Net Income(TTM)-14.41M

Analysts84.44

Price Target20.21 (210.92%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)4.73%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)-122.11%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)-34.56%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	49.47
P/FCF	N/A
P/OCF	N/A
P/B	4.64
P/tB	5.79
EV/EBITDA	N/A

EPS(TTM)-1.14

EYN/A

EPS(NY)-1.15

Fwd EYN/A

FCF(TTM)-1.13

FCFYN/A

OCF(TTM)-1.02

OCFYN/A

SpS0.13

BVpS1.4

TBVpS1.12

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-39.08%
ROE	-75.9%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	61.55%
FCFM	N/A

ROA(3y)-45.31%

ROA(5y)-32.39%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-5.33%

GM growth 5YN/A

F-Score4

Asset Turnover0.05

Health

		Industry Rank	Sector Rank
Debt/Equity	0.81
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	152.56%
Cap/Sales	85.33%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	11.36
Quick Ratio	11.15
Altman-Z	1.34

F-Score4

WACC8.33%

ROIC/WACCN/A

Cap/Depr(3y)276.3%

Cap/Depr(5y)321.58%

Cap/Sales(3y)395.7%

Cap/Sales(5y)363.64%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-26.52%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-11.8%

EPS Next Y-34.32%

EPS Next 2Y-7.14%

EPS Next 3Y2.5%

EPS Next 5Y10.34%

Revenue 1Y (TTM)198.49%

Revenue growth 3Y40.28%

Revenue growth 5Y35.8%

Sales Q2Q%257.93%

Revenue Next Year50%

Revenue Next 2Y141.52%

Revenue Next 3Y132.08%

Revenue Next 5Y97.35%

EBIT growth 1Y-44.55%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-44.54%

EBIT Next 3Y4.32%

EBIT Next 5Y15.28%

FCF growth 1Y-134.11%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-163.49%

OCF growth 3YN/A

OCF growth 5YN/A

4BASEBIO PLC / 88Q.DE FAQ

Can you provide the ChartMill fundamental rating for 4BASEBIO PLC?

ChartMill assigns a fundamental rating of 3 / 10 to 88Q.DE.

Can you provide the valuation status for 4BASEBIO PLC?

ChartMill assigns a valuation rating of 0 / 10 to 4BASEBIO PLC (88Q.DE). This can be considered as Overvalued.

How profitable is 4BASEBIO PLC (88Q.DE) stock?

4BASEBIO PLC (88Q.DE) has a profitability rating of 1 / 10.

What is the earnings growth outlook for 4BASEBIO PLC?

The Earnings per Share (EPS) of 4BASEBIO PLC (88Q.DE) is expected to decline by -34.32% in the next year.

4BASEBIO PLC (88Q.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

4BASEBIO PLC / 88Q.DE FAQ

Can you provide the ChartMill fundamental rating for 4BASEBIO PLC?

Can you provide the valuation status for 4BASEBIO PLC?

How profitable is 4BASEBIO PLC (88Q.DE) stock?

What is the earnings growth outlook for 4BASEBIO PLC?